Eswar Krishnan, MD

Drug Development Executive

Science EN ↓ Епізодів: 10

Welcome to our podcast, designed specifically for biotech executives passionate about drug development. Join us as we explore a wide range of engaging topics, from cutting-edge advancements in translational sciences to the latest regulatory updates. Let’s navigate this dynamic landscape together and stay ahead of the curve! www.drugdevelop.com

Обов'язково відвідайте сайт подкасту та підтримайте його автора: www.drugdevelop.com

Автор

Eswar Krishnan, MD

Категорія

Science

Сайт подкасту

www.drugdevelop.com

Останній епізод

18 лип 2025

Де слухати?

Подкасти в застосунку Replaio Radio Уже незабаром

Подкасти незабаром з'являться в застосунку. Встановіть уже зараз і першими побачте зовсім новий погляд на подкасти

Встановіть безкоштовно Android майже 10 млн завантажень · рейтинг 4,8 iOS незабаром

Епізоди

State Of The Art in SLE: For Biotech CMOs and CSOs 18.07.2025 45:47

This podcast summarizes the therapeutic landscape and the underlying molecular understanding of the causal pathways in lupus. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com

mAbs vs CAR-T: A Head-to-Head Comparison for CMOs and CSOs 14.07.2025 29:50

CAR-T Illustration. Courtesy New Scientist A recent head-to-head study assessed the comparative effectiveness of different B-cell depletion strategies in patients with autoimmune diseases, specifically comparing protein-based therapies like obinutuzumab (OBI), blinatumomab (BLI), and rituximab (RTX) with cell-based CD19 chimeric antigen receptor (CAR) T-cell therapy . Researchers analyzed lymph no...

Type 5 Diabetes: For CMOs and CSOs 07.07.2025 5:49

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com

B-cell depletion for autoimmune diseases: For Biotech CMOs and CSOs 06.07.2025 17:27

New B cell depleters in development may offer superior impact on the immune system, durably "reset" the immune system, potentially cure conditions like pre-Type 1 Diabetes and SLE, or allow celiac disease patients to tolerate gluten again. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com

Interleukin-6 and Cardioimmunology: For CMOs and CSOs 03.07.2025 16:27

This podcast discusses the role of inflammation, specifically interleukin-6 (IL-6) signaling, in cardiovascular diseases (CVD), including atherosclerosis and myocardial infarction (MI). We discuss the therapeutic potential of blocking IL-6 or its receptor (IL-6R) with drugs like tocilizumab and ziltivekimab, highlighting their ability to reduce inflammatory markers, such as C-reactive protein (CRP...

CAR T-Cell Therapy trials in Lupus just got a bit easier: For Biotech CMOs and CSOs 29.06.2025 48:16

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com

Fast Approvals with FDA's Voucher Programs: For Biotech CMOs and CSOs 29.06.2025 31:52

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com

Digital Twins For Biotech CMOs and CSOs 24.06.2025 40:59

This is an audio companion to the blog post in Substack This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com

Digital Twins for CSOs and CMOs 21.06.2025 40:59

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com

FDAs Recent Roundtable on Cell and Gene Therapies 08.06.2025 17:46

This podcast summarizes the FDA roundtable conducted on June 6, 2025. The original source is provided here This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com